Taiwan · Delayed Price · Currency is TWD Sofiva Genomics Statistics
Total Valuation
Sofiva Genomics has a market cap or net worth of TWD 727.70 million. The enterprise value is 638.82 million.
| Market Cap | 727.70M |
| Enterprise Value | 638.82M |
Important Dates
The next estimated earnings date is Friday, May 15, 2026.
| Earnings Date | May 15, 2026 |
| Ex-Dividend Date | Jun 27, 2025 |
Share Statistics
Sofiva Genomics has 21.59 million shares outstanding. The number of shares has increased by 0.58% in one year.
| Current Share Class | 21.59M |
| Shares Outstanding | 21.59M |
| Shares Change (YoY) | +0.58% |
| Shares Change (QoQ) | +3.23% |
| Owned by Insiders (%) | 5.59% |
| Owned by Institutions (%) | n/a |
| Float | 12.64M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.89 |
| PB Ratio | 1.16 |
| P/TBV Ratio | 1.17 |
| P/FCF Ratio | 51.25 |
| P/OCF Ratio | 47.39 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 20.50, with an EV/FCF ratio of 44.99.
| EV / Earnings | -68.25 |
| EV / Sales | 1.66 |
| EV / EBITDA | 20.50 |
| EV / EBIT | n/a |
| EV / FCF | 44.99 |
Financial Position
The company has a current ratio of 3.33, with a Debt / Equity ratio of 0.06.
| Current Ratio | 3.33 |
| Quick Ratio | 2.70 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | 4.52 |
| Debt / FCF | 2.50 |
| Interest Coverage | -39.83 |
Financial Efficiency
Return on equity (ROE) is -1.39% and return on invested capital (ROIC) is -6.13%.
| Return on Equity (ROE) | -1.39% |
| Return on Assets (ROA) | -2.83% |
| Return on Invested Capital (ROIC) | -6.13% |
| Return on Capital Employed (ROCE) | -5.16% |
| Weighted Average Cost of Capital (WACC) | 5.49% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.52 |
| Inventory Turnover | 7.05 |
Taxes
In the past 12 months, Sofiva Genomics has paid 551,000 in taxes.
| Income Tax | 551,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -13.59% in the last 52 weeks. The beta is 0.26, so Sofiva Genomics's price volatility has been lower than the market average.
| Beta (5Y) | 0.26 |
| 52-Week Price Change | -13.59% |
| 50-Day Moving Average | 33.18 |
| 200-Day Moving Average | 31.99 |
| Relative Strength Index (RSI) | 43.72 |
| Average Volume (20 Days) | 31,588 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Sofiva Genomics had revenue of TWD 385.71 million and -9.36 million in losses. Loss per share was -0.43.
| Revenue | 385.71M |
| Gross Profit | 99.13M |
| Operating Income | -33.74M |
| Pretax Income | -8.30M |
| Net Income | -9.36M |
| EBITDA | 7.87M |
| EBIT | -33.74M |
| Loss Per Share | -0.43 |
Balance Sheet
The company has 124.71 million in cash and 35.53 million in debt, with a net cash position of 89.18 million or 4.13 per share.
| Cash & Cash Equivalents | 124.71M |
| Total Debt | 35.53M |
| Net Cash | 89.18M |
| Net Cash Per Share | 4.13 |
| Equity (Book Value) | 628.43M |
| Book Value Per Share | 28.18 |
| Working Capital | 165.30M |
Cash Flow
In the last 12 months, operating cash flow was 15.36 million and capital expenditures -1.16 million, giving a free cash flow of 14.20 million.
| Operating Cash Flow | 15.36M |
| Capital Expenditures | -1.16M |
| Depreciation & Amortization | 41.61M |
| Net Borrowing | -15.25M |
| Free Cash Flow | 14.20M |
| FCF Per Share | 0.66 |
Margins
Gross margin is 25.70%, with operating and profit margins of -8.75% and -2.43%.
| Gross Margin | 25.70% |
| Operating Margin | -8.75% |
| Pretax Margin | -2.15% |
| Profit Margin | -2.43% |
| EBITDA Margin | 2.04% |
| EBIT Margin | -8.75% |
| FCF Margin | 3.68% |
Dividends & Yields
This stock pays an annual dividend of 0.30, which amounts to a dividend yield of 0.89%.
| Dividend Per Share | 0.30 |
| Dividend Yield | 0.89% |
| Dividend Growth (YoY) | 50.77% |
| Years of Dividend Growth | 1 |
| Payout Ratio | n/a |
| Buyback Yield | -0.58% |
| Shareholder Yield | 0.31% |
| Earnings Yield | -1.29% |
| FCF Yield | 1.95% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Sofiva Genomics has an Altman Z-Score of 5.38 and a Piotroski F-Score of 3.
| Altman Z-Score | 5.38 |
| Piotroski F-Score | 3 |